What Sumitovant does

Sumitovant Biopharma Ltd. is a private biopharmaceutical subsidiary of Sumitomo Pharma Co., Ltd., headquartered in New York, United States, and domiciled under the Japanese parent group. Founded in 2019 and operating with 251–500 employees, the company focuses on drug discovery, development, and commercialization across six core therapeutic areas: oncology, women's health, urology, rare disease, CNS, and cell & gene therapies. Its commercial-stage portfolio is anchored by ORGOVYX (prostate cancer) and MYFEMBREE (women's health), both inherited through the March 2023 acquisition of Myovant Sciences Ltd. for $1.7 billion.

The company's core technology is a diversified preclinical and clinical pipeline targeting unmet medical needs, supported by wholly-owned subsidiaries including Myovant Sciences Ltd. (women's health and prostate cancer) and Sumitomo Pharma America, Inc. (U.S. regional operations). Sumitovant's go-to-market leverages the global distribution and regulatory infrastructure of Sumitomo Pharma, the parent conglomerate. Revenue mechanics are not publicly disclosed, but commercial product sales from ORGOVYX and MYFEMBREE, alongside potential pipeline out-licensing, represent the primary monetization paths. The end customer base is fragmented across patients and prescribing physicians in the company's therapeutic areas, with no large enterprise anchor customers disclosed. Strategic direction, capital, and distribution flow entirely through Sumitomo Pharma, positioning Sumitovant as the U.S.- and oncology/urology-focused commercial arm of a larger Japanese pharmaceutical group.

Name

Sumitovant

Legal name

Sumitovant Biopharma Ltd.

Website

https://sumitovant.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

251–500 employees

Short description

Sumitovant is a private biopharmaceutical subsidiary of Sumitomo Pharma that develops and commercializes therapeutics across oncology, women's health, urology, rare disease, CNS, and cell & gene therapies, serving patients and prescribers in the U.S. and worldwide.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Nephrology & Urology Pharmaceuticals (HLAIAAAM), Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

Keywords

• Biopharmaceutical development
• Drug discovery
• Oncology therapeutics
• Women's health treatments
• Rare disease therapies

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Core offering

Sumitovant Biopharma is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines in critical therapeutic areas including oncology, women's health, urology, rare disease, CNS, and cell & gene therapies. The company operates a diverse preclinical and clinical pipeline and markets approved products such as ORGOVYX and MYFEMBREE for prostate cancer and women's health conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• ORGOVYX

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Myovant SciencescoreStrategic or Co-development PartnerSumitovant Biopharma and Sumitomo Pharma proposed to acquire all outstanding shares of Myovant Sciences for $22.75 per share, valued at $2.4 billion equity. The transaction aimed to create value for shareholders and integrate resources in women's health and prostate cancer therapies including ORGOVYX and MYFEMBREE.
• Myovant SciencescoreStrategic or Co-development PartnerMyovant Sciences was acquired by Sumitovant Biopharma for $1.7 billion with transaction expected to close Q1 2023. The deal was unanimously approved by boards of both companies and a special committee of Myovant's independent directors.
• Myovant SciencescoreStrategic or Co-development PartnerIn March 2023, Sumitovant Biopharma completed acquisition of Myovant Sciences for $1.7 billion to combine expertise and accelerate development of novel therapies including ORGOVYX and MYFEMBREE in women's health and prostate cancer.

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Astellas Pharma: Astellas directly competes with Sumitovant in urology/prostate cancer via Xtandi (enzalutamide), the established standard of care against which ORGOVYX is positioned. Both companies operate specialty pharma models focused on oncology and urology.
• Takeda Pharmaceutical: Takeda is a large Japanese-headquartered specialty pharma with oncology, women's health, rare disease, and CNS franchises, closely mirroring Sumitovant's therapeutic breadth under a parent-affiliated operating model.
• Ipsen: Ipsen is a specialty pharma with a strong urology and oncology footprint (including Decapeptyl/Trelstar in prostate cancer) and rare disease programs, making it a direct competitor to Sumitovant in urology with a comparable specialty-focused commercial model.

Broad incumbents

• AbbVie: AbbVie competes with Sumitovant's MYFEMBREE through its elagolix franchise (Orilissa/Oriahnn) in women's health, while also operating a broad specialty pharma portfolio across oncology, neuroscience, and immunology.
• Bristol-Myers Squibb: BMS markets Erleada (apalutamide) for prostate cancer, directly overlapping with Sumitovant's ORGOVYX, and operates a broader oncology and specialty therapeutics portfolio under a similar commercialization model.
• Pfizer: Pfizer co-promotes Xtandi with Astellas in prostate cancer, competing with ORGOVYX, and operates a broad oncology and women's health portfolio that overlaps multiple Sumitovant therapeutic areas.
• Bayer: Bayer has established franchises in women's health and oncology (including Nubeqa for prostate cancer), making it both a therapeutic-area and commercial-model peer to Sumitovant across multiple of its focus indications.
• Roche: Roche operates a broad specialty pharma and oncology portfolio with deep women's health and CNS adjacencies, providing scale, R&D, and commercialization benchmarks relevant to Sumitovant's growth trajectory.

Regional players

• Daiichi Sankyo: Daiichi Sankyo is a Japanese-headquartered pharma with growing specialty and oncology presence (e.g., ADC platform); comparable to Sumitovant in therapeutic focus and parent-affiliated structure, primarily serving overlapping global markets from a Japan base.

Emerging players

• Organon & Co. Organon is a specialty pharma spun out of Merck focused on women's health, biosimilars, and established brands, overlapping directly with Sumitovant's MYFEMBREE franchise in women's health therapeutic areas.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/sumitovant
• LinkedInlinkedin.com/company/sumitomo-pharma-america

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sumitovant